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Legend 
Abbreviation Full description 
MI Myocardial Infarction 
SHAM Sham-operated mice 
NO Non Operated mice 
BZ Infarct Border Zone 
RA Infarct Remote Area  
CLVs Cardiac Lymphatic Vessels 
LVs Lymphatic vessels  
LECs Lymphatic Endothelial Cells 
BVs Blood vessels 
ECs Endothelial cells (blood) 
ECM Extra Cellular Matrix 
EMT Epithelial Mesenchymal Transition 
FRCs Fibroblastic Reticular Cells 
CAF Cancer Associated Fibroblast 
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Abstract 
Cardiovascular diseases, including myocardial infarction (MI) and heart failure, are the leading 
causes of death in the industrialized world. The epidemic problem of cardiomyopathies, together 
with the limitation of their management, constitutes the basis for the current interest in 
regenerative cardiology. Restoration of the cardiac function is one of the main aims of the 
cardiovascular research community. Although there are continuous news and scientific papers 
about clinical trials of cardio-protective drugs and new approaches with the stem cell-based 
therapies, the knowledge regarding the scar formation after MI or non-ischemic 
cardiomyopathies is confined to the discoveries from decades ago. Thus, there is still a question 
that has to be addressed: what happens during the healing process of scar formation? 
The repair and regeneration of the injured tissue are inter-related. In some instances, a 
regenerative process of endogenous new cardiomyocyte formation and neo-vascularization occur 
concomitantly with the scar development. Unfortunately, physiologically the regeneration is 
much less pronounced than the replacement fibrosis. As said, cardiac scars are dynamic living 
structures, although, the blood vascular rarefaction and the poor neo-angiogenesis contribute to 
the deleterious effects of the cardiac inflammation and edema. However, the crucial role in the 
maintenance of tissue fluid balance and immune surveillance is played by the lymphatic system, 
suggesting that the lymphangiogenesis in the process of scarification is very important for the 
heart healing. The lymphatic system is present throughout the entire body in all vertebrates and 
regulates the tissue homeostasis, fluid balance and repair due to its function in the transport of 
molecules and cells. The unique structure of the lymphatic vessels (LVs) such as, discontinuous 
basal lamina, fenestrations, wide lumen and lack of pericyte and smooth muscle cell lining, are 
advantageous features for cell trans-migration and diapedesis. Hence, functional LVs are critical 
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for the circulation-trafficking of immune, cancer and other cell types. Cardiac lymphatic 
vasculature undergoes substantial expansion in response to MI; however, there is limited 
information on the cellular mechanisms mediating post-MI lymphangiogenesis and 
accompanying fibrosis. In the heart, the cardiac lymphatic system is crucial for the control of 
intra-myocardial pressure and prevention of swelling, lipid transport and balanced regulation of 
tissue inflammation and there is a documented link between lymphatic malfunction and 
cardiovascular diseases. Using a mouse model of permanent coronary artery ligation, we 
examined spatiotemporal changes in the expression of lymphendothelial and mesenchymal 
markers in the acutely and chronically infarcted myocardium. We found that at the time of 
wound granulation, a three-fold increase in the frequency of podoplanin-labeled cells occurred in 
the infarcted hearts compared to non-operated and sham-operated counterparts. Podoplanin is a 
very interesting protein; it is expressed in a variety of different type of cells and in different 
context; mostly orchestrates the lymphatic and the immune system but also the malignancy of 
tumors. It is known that a multitude of stimuli can drive podoplanin expression, including 
physiological differentiation factors in embryogenesis, potentially malignant factors such as pro-
tumorigenic signaling pathways in cancer and pro-inflammatory cytokines in immune diseases. 
In our study podoplanin immunoreactivity detected LYVE-1-positive LVs, as well as masses of 
LYVE-1-negative cells dispersed between myocytes, predominantly in the vicinity of the 
infarcted region. Podoplanin-carrying populations displayed a mesenchymal progenitor marker 
PDGFRα, and intermittently expressed Prox-1, a master regulator of the lymphatic endothelial 
fate. At the stages of scar formation and maturation, concomitantly with the enlargement of 
lymphatic network in the injured myocardium, the podoplanin-rich LYVE-1-negative 
multicellular assemblies were apparent in the fibrotic area, aligned with extracellular matrix 
4 
 
deposits, or located in immediate proximity to activated blood vessels with high VEGFR-2 
content. Of note, these podoplanin-containing cells acquired the expression of PDGFRβ or a 
hematoendothelial epitope CD34. Although Prox-1 labeling was abundant in the area affected by 
MI, the podoplanin-presenting cells were not consistently Prox-1-positive. The concordance of 
podoplanin with VEGFR-3 similarly varied. Based our observations, podoplanin is highly 
expressed not only by the lymphatic endothelial cells (LECs), but by different type of cells at the 
time of inflammation; this heterogeneous cell cohorts that express podoplanin contribute to scar 
tissue biology in early and advanced phases of scar maturation. Thus, our data reveal previously 
unknown phenotypic and structural heterogeneity within the podoplanin-positive cell 
compartment in the infarcted heart, and suggest an alternate ability of podoplanin-presenting 
cardiac cells to generate lymphatic endothelium and pro-fibrotic cells, contributing to scar 
development.  
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Riassunto  
Le malattie cardiovascolari rappresentano una delle principali cause di morte nel mondo 
industrializzato. Oggigiorno l’insufficienza cardiaca secondaria a infarto del miocardio o altre 
patologie è trattata esclusivamente su base sintomatica; la medicina rigenerativa ha l’ambizione 
di curare le cause della insufficienza cardiaca ripristinando il tessuto cardiaco danneggiato e 
limitando l’estensione del tessuto cicatriziale non funzionante. Sebbene ci sia una solida 
letteratura, comprensiva di studi clinici, sui farmaci cardioprotettivi e sulle terapie a base di 
cellule staminali, le conoscenze riguardanti la formazione della cicatrice secondaria a infarto del 
miocardico o a cardiomiopatie non ischemiche sono limitate a osservazioni di alcune decadi fa. 
Oggi, grazie alle nuove tecnologie e all’utilizzo di sonde molecolari, è possibile studiare con 
precisione gli stadi infiammatori che esitano nella formazione della cicatrice e lo sviluppo 
temporale di quest’ultima; tali informazioni sono di grandissima utilità per migliorare sia la 
somministrazione che la tipologia delle terapie cardioprotettive o riparative.  
Durante la formazione della cicatrice, la rigenerazione, ovvero la formazione di tessuto 
competente costituito da nuovi cardiomiociti e vasi sanguigni, è fisiologicamente molto meno 
pronunciata rispetto ai meccanismi che governano la fibrosi sostitutiva. Nelle fasi iniziali la 
rarefazione vascolare e la inefficiente neo-angiogenesi favoriscono gli eventi pro-fibrotici, quali 
infiammazione e l'edema interstiziale. L’omeostasi tessutale e la risoluzione dell’infiammazione, 
indispensabili per rallentare e contenere la formazione della cicatrice vengono modulati dal 
sistema linfatico. Il sistema linfatico ricopre un ruolo estremamente importante nella fisiologia 
della formazione della cicatrice e del processo rigenerativo. Il sistema linfatico è presente in tutto 
il corpo di tutti i vertebrati ove modula l’omeostasi tessutale grazie alla sua funzione di trasporto 
di molecole e cellule. I vasi linfatici sono caratterizzati da una struttura peculiare, presentano una 
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lamina basale discontinua, fenestrazioni tra le cellule dei vasi, un ampio lume e mancano del 
rivestimento pericitario e di cellule muscolari lisce, caratteristiche peculiari dei vasi ematici. 
Queste proprietà sono vantaggiose per la trans-migrazione cellulare e la diapedesi. Pertanto, i 
vasi linfatici sono fondamentali per la circolazione e distribuzione di cellule immunitarie, 
tumorali o di altro tipo. 
Nel cuore, il sistema linfatico è cruciale per il controllo della pressione intra-miocardica ed il 
trasporto dei lipidi, primaria fonte di energia dei cardiomiociti e subisce una notevole espansione 
in risposta all’infarto del miocardio, anche se vi sono limitate informazioni sui meccanismi che 
mediano la linfangiogenesi e la formazione della cicatrice post ischemica. In letteratura, sono 
presenti alcuni studi che descrivono il legame tra il malfunzionamento dei linfatici e le malattie 
cardiovascolari.  
Nel presente progetto di ricerca, usando un modello murino di legatura permanente dell'arteria 
coronaria discendente, abbiamo esaminato i cambiamenti spazio-temporali dell'espressione dei 
marcatori linfo-endoteliali e mesenchimali nel miocardio infartuato in fase acuta e cronica. 
Abbiamo osservato che nel tessuto di granulazione post ischemia vi è un notevole aumento 
dell’espressione della podoplanina, un marcatore linfatico che per la prima volta abbiamo trovato 
associato anche a cellule non linfatiche. La podoplanina è una proteina dalle sfaccettature molto 
interessanti; viene espressa da svariati tipi di cellule e in contesti diversi; per lo più governa il 
funzionamento del sistema linfatico e del sistema immunitario ma ha un ruolo importante nel 
predire la malignità dei tumori.  
Come atteso, nel tessuto ischemico cardiaco la podoplanina viene co-espressa insieme a LYVE-1 
dalle cellule endoteliali che formano i vasi linfatici; allo stesso tempo, abbiamo osservato 
numerose cellule podoplanina positive che co-esprimevano PDGFRα, marcatore di cellule 
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progenitrici mesenchimali, e,  in maniera meno costante, Prox-1, fattore di trascrizione deputato 
a regolare il lineage linfo-endoteliale; queste cellule podoplanina
+, PDGFRα+, Prox-1+/-, non 
delimitavano strutture vascolari, ma risultavano distribuite in maniera dispersa nel tessuto fibro-
infiammatorio post-infartuale.  
Nelle fasi di formazione e maturazione della cicatrice, in concomitanza con l’espansione della 
rete linfatica del miocardio danneggiato, le cellule podoplanina
+
 sono state osservate nell'area 
fibrotica, allineate con depositi di matrice extracellulare o situate nelle immediate vicinanze di 
vasi sanguigni positivi al VEGFR-2. Nella fase acuta dell’infarto, anche le cellule positive al 
PDGFRβ o al CD34 esprimevano la podoplanina rimanendo distribuite in maniera dispersa nello 
stroma fibro-infiammatorio. La co-espressione della podoplanina con il VEGFR-3, altro 
marcatore degli endoteli linfatici, risultava invece variabile rispetto al LYVE 1.  
Sulla base delle nostre osservazioni, nella cinetica post-ischemica del tessuto miocardico, la 
podoplanina viene espressa non solo dalle cellule endoteliali linfatiche, ma anche da altri tipi di 
cellule che partecipano alla fase acuta e cronica dell’infarto del miocardio, contribuendo in 
maniera importante alla modulazione del tessuto cicatriziale nelle varie fasi della riparazione del 
danno tessutale.  
In conclusione, questo studio ha confermato come i linfatici prendano parte al rimodellamento 
del tessuto fibro-infiammatorio post-infarto, rivelando una intensa e inattesa distribuzione del 
marcatore linfatico, podoplanina; i nostri dati evidenziano come la podoplanina venga espressa 
da cellule di diversa natura, alcune delle quali possibilmente implicate nell’indirizzare la 
riparazione miocardica verso la fibrosi cicatriziale; queste nuove conoscenze consentiranno di 
studiare in maniera più approfondita i meccanismi endogeni di rigenerazione, e di attivare o 
sopprimere pathway molecolari che finora non erano stati presi in considerazione. 
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Introduction 
How can we fix a broken heart?  
Love heals broken hearts but not cardiac wounds.  
Cardiovascular diseases, including myocardial infarction (MI) and heart failure, are the leading 
causes of death in the industrialized world. The epidemic problem of cardiomyopathies, together 
with the limitation of their management, constitutes the basis for the current interest in 
regenerative cardiology. Restoration of the cardiac function is one of the main aims of the 
cardiovascular research community. Although there are continuous news and scientific papers 
about clinical trials of cardio-protective drugs and new approaches with the stem cell-based 
therapies, the knowledge regarding the scar formation after MI or non-ischemic 
cardiomyopathies is confined to the discoveries from decades ago. Thus, there is still a question 
that has to be addressed: what happens during the healing process of scar formation? 
MI may be the most common cause of ventricular scarring in humans, scars also occur in non-
ischemic cardiomyopathies due to replacement fibrosis  during both pressure/volume overload 
[1] and normal ageing [2], although aging is not necessarily associated with fibrosis per se [3]. In 
addition, scars result from clinical interventions such as ablation and surgical procedures [4].  
‘Fibrosis’ is not synonymous with an elevated presence of interstitial cells: it is quantified 
through the presence of collagen – a key component of the acellular fraction of connective tissue. 
Fibrotic scars, such as in skin, are generally acellular and predominantly composed of fibrillar 
collage [5]. In the heart, however, scar tissue assumes a more proactive role than simply 
preserving ventricular integrity, facilitating force transmission, and preventing rupture. 
Nonetheless, myocardial scarring does share common mechanisms and morphological 
milestones with classic wound healing (reviewed in [6] [7]).  
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Briefly, injury is followed by spreading tissue necrosis, neutrophil infiltration, and macrophage-
driven clean-up of cellular debris. Subsequently, granular tissue formation, neovascularization, 
and (partial) sympathetic re-innervation occur. Infiltration from intra- and extra-cardiac sources 
and proliferation of fibroblast-like cells occurs throughout, and is observed as early as a few 
hours post-injury [8] [9]. Large amounts of newly produced collagen act to reinforce the healing 
tissue, eventually establishing a steady state involving balanced extracellular matrix (ECM) 
production by fibroblasts and degradation via matrix metalloproteinases that are released by 
leukocytes, fibroblasts, and smooth muscle cells [10]. The traditional view of scar formation 
(based on observations in organs such as skin) suggests that healing is followed by apoptosis of 
the vast majority, if not all, of the cells (including fibroblasts), leaving a mature, fibrillar scar. 
This whole process takes several weeks post-injury, and – in the heart at least – takes place in an 
environment of rhythmically changing stress and strain. 
Below (Fig 1) is shown a cross-section of an infarcted mouse heart at one month after the left 
ventricular descendent coronary artery ligation. The heart section is stained with the Masson 
trichrome staining; it is well recognizable the scar/fibrotic area colored in blue.   
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Fig 1. Scar formation after MI in a mouse hearth. Thin cardiac cross section of mouse heart at 
one month after MI was stained with Masson trichrome staing, the border zone of the MI and the 
newly formed fibrotic tissue is magnified on the left.  
 
The Living Scar 
Despite prevailing perceptions, cardiac scars are dynamic living structures [11]. The abundantly 
present ECM is interlaced with phenotypically diverse groups of cells: interstitial fibroblast-like 
cells, functionally and structurally heterogeneous, endothelial cells, vascular smooth muscle 
cells, surviving cardiomyocytes, immune cells, neurons, adipocytes and several type of 
progenitor cells such as endothelial progenitor cells (EPCs), pericytes, mesenchymal stem cells 
and cardiac progenitor cells (CPCs). The scar is a metabolically dynamic tissue which 
furthermore, exhibits non-linear passive and active mechanical properties; ‘active’ force-
generation by non-myocytes over time occurs at scales that are orders of magnitude longer than 
the heartbeat [12]. Contractile properties of the scar rely on the presence of non-vascular, α-
smooth muscle actin-expressing non-myocytes, which persist in cardiac scars for many years 
following injury, such as with MI [13]. Note that not all subsets of fibroblasts express contractile 
proteins [14]. They also depend on the presence of an extensive cytoplasmic fibrillar system of 
cell-to-cell and cell-to-ECM attachments [15]. 
The impact of scar tissue on cardiac electrical activity is a matter of debate [16]. Fibrosis can 
exhibit variable degrees of density, from focal and compact (in the case of scars) to patchy and 
diffuse. This can lead to the separation of strands of myocardium, forcing excitation waves to 
take anisotropic, circuitous paths [17] that may set the stage for re-entry of excitation [18]. 
Although fibrosis is strongly associated with an elevated risk of arrhythmogenesis, it is not well 
11 
 
understood how exactly it is involved in either the active generation or the passive maintenance 
of abnormal electrical conduction episodes. 
In some instances, a regenerative process of endogenous new cardiomyocyte formation and neo-
vascularization occur concomitantly with the scar development. The repair and regeneration of 
the injured tissue are inter-related. Unfortunately, physiologically the regeneration is much less 
pronounced than the replacement fibrosis [19].  
 
The healthy scar formation 
As said, cardiac scars are dynamic living structures [11] although, the blood vascular rarefaction 
and the poor neo-angiogenesis contribute to the deleterious effects of the cardiac inflammation 
and edema [20].  
However, the crucial role in the maintenance of tissue fluid balance and immune surveillance is 
played by the lymphatic system, suggesting that the lymphangiogenesis in the process of 
scarification is very important for the heart healing [21].    
The lymphatic system is present throughout the entire body in all vertebrates and regulates the 
tissue homeostasis, fluid balance and repair due to its function in the transport of molecules and 
cells [21]. 
The unique structure of the lymphatic vessels (LVs) such as, discontinuous basal lamina, 
fenestrations, wide lumen and lack of pericyte and smooth muscle cell lining, are advantageous 
features for cell trans-migration and diapedesis [21] . Hence, functional LVs are critical for the 
circulation-trafficking of immune, cancer and other cell types. . The lymphatic markers, function 
and features are summarized in the table below (Fig 2). 
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Fig 2. Characteristics of lymphatic vessels. In the table are summarized the major markers of 
the lymphatic endothelial cells and their role in the tissues all over the body. 
 
The Lymphangiogenesis  
The lymphatic vascular system is closely related to the blood vascular system in terms of origin, 
morphogenesis, and the regulatory molecules required for its development and growth. The 
lymphatic system develops in parallel and secondarily to the blood vascular system through 
lymphangiogenesis [22]. As revealed by lineage tracing, lymphatic endothelial cells (LECs) are 
differentiated entirely from venous endothelial cells in a process controlled by the transcription 
factor prospero homeobox-1 (Prox-1). Migrated LECs then form primary lymph sacs from which 
LECs germinate, proliferate, and migrate to give rise to the entire lymphatic vascular network. 
Vascular endothelial growthfactor-3 (VEGF-3) is a critical regulator for LVs growth, acting via 
its receptor, VEGFR-3, which is primarily found on LECs [23]. Initial differentiation of the 
LECs lineage begins from venous endothelial cells (ECs) [24]. Through yet-unknown 
mechanisms, a subset of venous ECs starts to become committed to the lymphatic endothelial 
fate at embryonic day (E) E8.5. These cells express the transcription factor Sox18, which directly 
activates Prox1 by binding to its proximal promoter. Transcription factor Prox-1 then serves as 
master regulator of LECs identity during embryonic development and postnatal remodeling [25]. 
Besides Prox-1, differentiating LECs at E9.5 also express lymphatic endothelial hyaluronan 
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receptor-1 (LYVE-1) and VEGFR-3. Starting at E10.5, podoplanin, a type-1 transmembrane 
sialomucin-type O-glycoprotein is expressed on the LECs surface. LECs, stimulated by vascular 
endothelial growth factor C (VEGF-C) secreted from adjacent tissue, migrate and proliferate to 
form primary lymph sacs around E11.5. During this step, the lymphatic and venous systems 
become separated via a process that involves podoplanin, [26]. Podoplanin activates C-Type 
lectin receptor 2 (CLEC-2), thus activating the hematopoietic protein Syk/Slp-76 signaling 
pathway and platelet aggregation. Aggregated platelets “seal off” the lymph sacs from cardinal 
veins [27]. Finally, LVs maturation and remodeling occur in a stepwise manner, leading to the 
formation of the complete lymphatic network. 
In the cartoon below (Fig 3) are summarized the Steps of mouse lymphangiogenesis [28]. 
 
Fig 3. The embryonal lymphangiogenesis. At E8.5, cardinal vein ECs become lympsatic 
competent. At E9–E9.5, a subset of cardinal vein ECs begins expressing Sox18 and 
subsequently, Prox-1 at E9.75. Starting at E10.5, podoplanin is expressed in ECs. At E11.5, 
primary lymph sac is formed from sprouted LECs, with aggregate platelets to seal and separate 
from the vein. Mature LVs are then developed from the primary lymph sac. Prox-1 and possibly 
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podoplanin are critical not only for separating blood and lymphatic vascular system, but also for 
maintaining LECs identity. 
 
The lymphangiogenesis: Prox-1 leads the transcription of podoplanin 
Mouse Prox-1 was named as such because of its homology to the Drosophila homeobox protein 
prospero [29]. During mouse embryogenesis, Prox-1 is expressed in the developing central 
nervous system (CNS), eye lens, pancreas, liver, skeletal muscles, and heart. Mice with 
tamoxifen induced deﬁciency of Prox-1 (inducibleProx1–/–) during the embryonic, postnatal, or 
adult stages exhibit interconnected blood vessels (BVs) and LVs and show dedifferentiation of 
LECs into ECs; reduced expression of LECs markers (VEGFR-3, podoplanin, LYVE-1, etc.) and 
the appearance of ECs markers (endoglin, CD34, etc.) may also be notably observed [28]. These 
ﬁndings indicate that LECs differentiation is tightly regulated and that the differentiated LECs 
phenotype is a plastic and dynamic condition that depends on constant Prox-1 activity, for 
maintenance. However, downstream target genes of Prox-1, through which it controls the switch 
from ECs to LECs and maintains LECs identity, remain to be identiﬁed. In vitro, Prox-1 interacts 
with transcription factor COUPTFII to regulate expression of several lineage genes, including 
VEGFR-3, ﬁbroblast growth factor receptor 3 (FGFR-3), and neuropilin 1 [22] [30]. However, 
phenotypes of mice lacking VEGFR-3, FGFR-3, or neuropilin 1 do not resemble the lymphatic 
defects in inducible Prox-1–/– mice [30]. When Prox-1 was adenovirally transduced into human 
dermal microvascular endothelial cells, expression of podoplanin was upregulated. Mice with 
global deletion of Podoplanin (Pdpn–/–) exhibit misconnected BVs and LVs that closely 
resemble those observed in inducible Prox-1–/– mice [31]. Both Prox-1 and podoplanin are also 
constantly expressed in LECs naturally and appear to function in an LEC-autonomous manner. 
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Thus, podoplanin is hypothesized to function downstream of Prox-1, and podoplanin expression 
is regulated by Prox-1 in LECs at the transcriptional level. Four putative binding elements for 
Prox1 in the 5′ upstream regulatory region of the podoplanin gene were ﬁrst identiﬁed. Using 
chromatin immunoprecipitation assay, Prox-1 was observed to directly bind to the 5′ regulatory 
sequence of the podoplanin gene in LECs. DNA pull down assay conﬁrmed that Prox-1 binds to 
the putative binding element. In addition, luciferase reporter assay indicated that Prox-1 binds to 
the 5′ regulatory sequence of podoplanin to regulate podoplaningene expression [32]. These 
results suggest that Prox-1 regulates podoplanin expression at the transcriptional level in the 
lymphatic vascular system. Thus, podoplanin potentially serves as a major downstream target 
gene of Prox-1 in the pathway essential for differentiation and maintenance of lymphatic 
identity. As described, mature LECs express Lyve-1, VEGFR-3, Prox-1 andpodoplanin; all of 
those protein and transcription factors are very important for the formation and, scientifically, for 
the identification of the LVs.  
The heart depends heavily on its lymphatic network for the return of the blood circulation of 
extravasated molecules and fluids. Accordantly, surgical obstruction of cardiac lymphatics 
rapidly leads to myocardial edema with well-described acute, and chronic, as well deleterious, 
effect on cardiac function [21].  
In the cartoon below (Fig 4) is described the mechanism of BVs and LVs separation [28]. 
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Fig 4. The separation of the lymphatic vessels from the cardinal vein. Podoplanin is O-
glycosylated during biosynthesis in LECs. Cell surface exposed podoplanin binds to platelet 
receptor CLEC-2 and activates the Syk tyrosine kinase and SLP-76 adaptor protein. Syk/SLP-76 
signaling leads to downstream activation of phospholipase C-γ2 (PLC-γ2), resulting in platelet 
activation. Aggregated platelets form a plug to seal off the growing primary lymph sac from the 
cardinal vein. 
 
The lymphatic system in the heart 
In the heart, the cardiac lymphatic system is crucial for the control of intra-myocardial pressure 
and prevention of swelling, lipid transport (major source of energy for myocytes), and balanced 
regulation of tissue inflammation (reviewed in [33] [34]). Although little is known about the 
distribution and activity of cardiac lymphatic vessels (CLVs), there is a documented link 
between lymphatic malfunction and cardiovascular diseases, including post-MI edema, fibrosis 
and scarring, and the evolution of congestive heart failure [35] [36].  
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Based on the hitherto reported data, the adult cardiac lymphatic vasculature consists of a network 
of sub-epicardial and sub-endocardial vessels and a plexus of myocardial capillaries of various 
diameters and variable concentrations in the different regions of the heart [37] [34] [38] [39]. 
The intramyocardial lymphatics drain centrifugally, with each contraction, toward the superficial 
epicardial lymphatic network composed of both blunt-ended capillaries and larger precollectors 
and valved collecting ducts, with empty into periaortic and paratracheal lymph nodes [21]. 
By employing immunohistochemical labeling LYVE-1, Prox-1, VEGFR-3, it was established 
that the localization and morphology of CLVs are substantially altered in pathological conditions 
[40] [21, 36]. Acutely after MI, the density of CLVs increases in the early phases of wound 
granulation and is further elevated at later stages of tissue repair, superseding the number of 
blood vessels (BVs) in the scar  [36] [41] [21]. The post-MI lymphangiogenesis in the human 
heart is mostly apparent in the scar, infarct border zone (BZ) and reactive pericarditis [36]. 
Likewise, in murine models of MI, the development of new CLVs is primarily detected in 
severely damaged myocardium and the adjacent BZ [42] [43]. There is evidence that CLVs are 
involved in adverse ventricular remodeling [42], potentially promoting the maturation of fibrosis 
and formation of a stable scar [41] [43]. Yet, experimentally-induced impairment in cardiac 
lymph flow leads to exacerbated and prolonged inflammation after MI [33] [35],
 
and promoting 
post-MI lymphangiogenesis is suggested to facilitate structural and functional recovery of the 
mouse  and rat  hearts [44] [21]. Thus, lymphangiogenic processes in the infarcted heart may 
have pleiotropic effects on the fibrogenic responses and scar maintenance.  
Importantly, the cellular sources of the CLVs in the healing MI remain to be revealed. In order to 
recognize putative cell populations participating in post-MI lymphangiogenesis and fibrosis 
during different phases of the wound repair, we performed characterization of the distribution of 
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an established lymphendothelial epitopes, podoplanin, LYVE-1, Prox-1 and VEGFR-3, along 
with the analysis of cell phenotypic markers associated with angiogenic and fibrogenic 
responses, including CD34, platelet-derived growth factor receptor (PDGFR) α and PDGFRβ, 
vimentin, and α-smooth muscle actin (α-SMA). Our data point to an unexpected heterogeneity in 
the podoplanin-positive cardiac cell compartment, which might be significant for the processes 
of CLV growth after injury, development of fibrosis and scar maintenance.  
In the three pictures (Fig 5) is shown the lymphatic vasculature in blue and the blood vasculature 
in white in thick sections of a mouse heart. Respectively from the left were pictured the 
epicardium, mid-myocardium and the endocardium; notice the distribution of the LVs along with 
the BVs and the major lymphatic collectors in the epicardium.  
 
           
Fig 5. The distribution of the lymphatic system in the heart. In the three pictures is shown the 
lymphatic vasculature in blue (LVs stained together with LYVE-1 and podoplanin) and the BVs 
in white (stained with isolectin B4) in thick sections (250μm) of a mouse heart. Respectively 
from the left was pictured the epicardium, mid-myocardium and the endocardium. In the 
epicardium are very well visible (on the right) the sub epicardial lymphatic collectors that are 
located under need the pericardium. The myocardial and the sub endocadial lymphatic 
vasculature run parallel to the blood vasculature in a very well orchestrate organization. 
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As expected, the distribution of the LVs in the scar is different compared to the healthy tissue, 
the lymphangiogenesis supersedes the angiogenesis as it is shown in the picture below (Fig 6). 
Notice that the lymphatic vasculature is stained in white and the blood vasculature in blue. In 
order to show the scar structure, the heart has been labeled in green with α-SMA. 
 
 
 
Fig 6. The distribution of the lymphatic system in the scaring heart. Below is shown a 3-D 
reconstruction of a thick section (250μm) of an infarcted mouse heart. Respectively the BVs are 
stained in blue with the isolectin B4 and the LVs are labeled in white with LYVE-1 and 
podoplanin. The scar tissue is stained with α-SMA, as a marker of fibrotic tissue. The section of 
the scar tissue, as it is shown before with the Masson trichrome staining is very thin. As said, 
during the scar formation the lymphangiogenesis superseding the angiogenesis.  
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Podoplanin, a small protein with many faces 
Based our observations, podoplanin is highly expressed not only by the LECs, but by different 
type of cells at the time of inflammation; this heterogeneous cell cohorts that express podoplanin 
contribute to scar tissue biology in early and advanced phases of scar maturation.  
Podoplanin is a 36- to 43-kDa mucin-type transmembrane protein. It has homologues in humans, 
mice, rats, dogs, and hamsters and is relatively well conserved between species. It has been 
reported to bind CLEC-2, which is highly expressed by platelets and immune cells; podoplanin 
also binds the CD44 and CD9 involved in cell motility and metastasis of immune and cancer 
cells [45]. 
podoplanin it has been identified and studied in many different contexts since it can be found on 
the surface of many types of cells originating from various germ layers. Thus, it has been given 
several names.  
Podoplanin was first described on LECs as the E11 antigen [46] and on fibroblastic reticular 
cells (FRCs) of lymphoid organs and thymic epithelial cells as gp38 [47]. Podoplanin is also 
homologous to T1a/rTI40, one of the first molecular markers of alveolar type I epithelial cells 
[48, 49], PA2.26, which is upregulated in skin keratinocytes upon injury [50], OTS-8, a molecule 
induced in osteoblasts upon phorbol ester treatment [51], and Aggrus, a platelet-aggregating 
factor [52]. Finally, this molecule was given the name podoplanin due to its expression on 
kidney podocytes and possible involvement in the flattening of podocyte foot processes [53].  
While podoplanin expression patterns in many of these cells have been well characterized, there 
is still little known about the physiological functions of this protein.  
Besides the lymphangiogenesis and LVs distribution, the setting in which podoplanin has been 
most extensively studied is cancer [45]. The link between the lymphangiogenesis and cancer is 
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correlated with poor prognosis in cancer patients with increased lymphangiogenesis [45]. PDPN 
is often used as a diagnostic marker [53] [54] [55]since is upregulated on tumor cells themselves 
in several cancer types, including squamous cell carcinoma of the lung, head, and neck [56] [57] 
[58] [59]malignant mesothelioma[60] [61] skin cancers, osteosarcomas, gliomas and brain 
tumors[62] [63]. Podoplanin is often expressed at the leading invasive edge of tumors and 
appears to play a role in Epithelial-Mesenchymal Transition (EMT), invasion, and metastasis 
[59]. Interactions between CLEC-2 and podoplanin in tumors also likely play a role in tumor 
progression and metastasis due to platelets interacting with tumor cells [64]. However, the exact 
mechanism of podoplanin action in tumor cells is still unclear; in some cases, podoplanin 
expression mediates the downregulation of E-cadherin and promotes EMT [57], while in others, 
podoplanin expression enhances tumorigenesis and metastasis in the absence of EMT [59]. In 
vitro studies have provided compelling evidence that forced expression of podoplanin in cells 
that normally lack this protein results in a more mesenchymal phenotype, actin-rich filopodia, 
and increased migration and invasion, as discussed above [57] [59]. 
Interestingly, podoplanin is also upregulated by cancer-associated fibroblasts (CAFs) in the 
stroma surrounding various tumors, including adenocarcinomas and colorectal cancers [65]. 
Generally, the expression of podoplanin on CAFs is associated with poor prognosis. While these 
studies illustrate that podoplanin expression in CAFs is linked to poor prognosis for patients, it is 
important to keep in mind that the effect of podoplanin
+
 CAFs likely depends on the type of 
tumor cells and the tissue from which the CAFs originate. In fact, one study of colorectal CAFs 
found that podoplanin expression was correlated with a better prognosis [66].  
Recently, the expression of podoplanin has been correlated with chronic inflammatory diseases 
characterized by hyper proliferation and an infiltrate of immune cells like psoriasis [67] and 
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rheumatoid arthritis [45]; not only, podoplanin is upregulated in experimental autoimmune 
encephalomyelitis (EAE), where it is believed to accelerate inflammation and disease 
progression [68]. We are the first in describing and characterizing the expression of podoplanin 
in the process of scarification in the heart.  
In the table below (Fig 7) are summarized the organs where podoplanin is expressed and its 
function [45]. 
 
Fig 7. Podoplanin expression and function. In the table are listed the major organs where 
podoplanin is expressed and its function along to the belonged organ. 
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The importance of podoplanin in the organ development 
Podoplanin is first expressed in the developing mouse embryo on day E9 in the foregut, 
proepicardial organ, and central nervous system [49] [69]. Throughout development, it is also 
expressed in the fetal rat kidney, choroid plexus, intestine, and esophagus [49]. Over time, 
podoplanin expression is increasingly restricted such that in an adult animal, podoplanin is 
predominantly expressed in alveolar type I cells, mature osteoblasts, LECs, and FRCs in the T 
cell zone of lymphoid organs  [46] [49] [58]. PDPN is critical for normal development of some 
of these organs and has been well studied in podoplanin-deficient animals. Pdpn
-/-
 mice develop 
normally until around day E10, which coincides with the appearance of podoplanin protein. 
From days E10–16, approximately 40% of podoplanin-/- embryos die; the ones that survive to 
birth die within a few days [69]. The defect in blood-lymphatic vascular separation is the 
phenotype most extensively studied in podoplanin-deficient mice. On day E11.5, podoplanin first 
appears in the developing circulatory system on Prox-1
+
 LECs [58]. It was first reported by 
Schacht et al. (2003) that podoplanin
-/-
 mice have abnormal LVs that cannot properly regulate 
lymph flow and that this defect did not appear in blood vessels. These findings were further 
supported by Fu et al. (2008), who reported that endothelial cell expression of podoplanin was 
responsible for a blood-lymphatic misconnection. Furthermore, continued expression of 
podoplanin into adulthood was required to maintain proper vascular architecture, as an inducible 
deletion of T-synthase, a major glycosyltransferase required for O-glycan synthesis and normal 
levels of podoplanin expression, showed similar blood-lymph mixing [31]. 
During the embryogenesis, the interaction of platelet CLEC-2 and podoplanin on LECs induces 
platelet aggregation and prevents blood from flowing into new LVs budding from the cardinal 
vein. Furthermore, injecting a podoplanin-blocking antibody or otherwise inhibiting platelet 
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aggregation is sufficient to disrupt lymphatic development [70]. Overall, the model that has 
emerged indicates that during the budding of the lymph sac from the cardinal vein, podoplanin 
becomes upregulated on Prox-1
+ 
LYVE-1
+
 LECs and binds with CLEC-2 on platelets. This 
interaction activates downstream signaling in platelets, which results in platelet aggregation. This 
aggregation then allows for a complete separation of the budding LVs from the developing BVs. 
In addition to its role in LVs development, podoplanin may play a role in the development or 
maintenance of lymphoid organ architecture, alveolar type I cells and alveoli structure and heart 
formation [45] 
Podoplanin is highly necessary for proper development of the heart. podoplanin is first expressed 
in the proepicardial organ on day E9.5 and by day E12.5, it is expressed in most of the heart. 
Without podoplanin expression, the hearts of developing mice exhibit hypoplasia in the 
pulmonary vein, left atrium dorsal wall, and the atrial septum  [71]. In this setting, the lack of 
Podoplanin leads to a dysregulation of EMT, a process that involves the transition of sessile 
epithelial cells into more motile mesenchymal cells through the downregulation of epithelial 
markers, such as adhesion molecules like E-cadherin [72]. In podoplanin-deficient mice, the 
epicardium-derived cells responsible for cardiac development show increased levels of E-
cadherin and decreased levels of RhoA compared with their wild-type counterparts, which is 
indicative of impaired EMT  [69]. While podoplanin has been shown to play a role in regulating 
EMT [57], these studies are the first evidence that podoplanin may play a role in physiological 
instances of EMT in non-transformed cells. 
Overall, podoplanin is crucial for the development of multiple organs interestingly, podoplanin 
serves diverse functions in these organs. In some instances it is required for CLEC-2-dependent 
platelet aggregation, but in others it seems to have an intrinsic effect on proliferation or 
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differentiation in a specific cell type [45]. This raises the question of whether podoplanin 
function could to some degree be tissue specific. The range of physiological effects downstream 
of podoplanin expression may be due to different protein interactions and binding partners in 
diverse cell types. 
In the cartoon below are summarized the main transcription factor and cytokines that can 
enhance and promote the podoplanin transcription (Fig 8) [45].   
 
Fig 8. Transcription of podoplanin. The transcription of podoplanin can be led by different 
type of stimuli; the major activators of the transcription are pro-inflammatory cytokines. 
 
Podoplanin signaling and molecular pathways  
Podoplanin contains a single transmembrane domain, a short, nine amino acid cytoplasmic tail, 
and a heavily glycosylated extracellular domain [57]. While there are no obvious conserved 
protein domains in podoplanin, several studies have identified specific residues on podoplanin 
that mediate interactions with other proteins. The first hints at the cellular function of podoplanin 
came from [50], who discovered that podoplanin was upregulated in keratinocytes from induced 
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epidermal carcinogenesis and was localized to membrane protrusions such as fillopodia and 
lamellipodia. Podoplanin co-localized with ezrin, radixin, and moesin (ERM) family proteins, 
and was later found to directly bind ezrin and moesin. The ERM proteins function as connectors 
between integral membrane proteins and the actin cytoskeleton. Thus, this interaction likely 
underlies many of the effects that podoplanin has on cytoskeleton.  
Podoplanin also interacts with two integral membrane proteins that could help to further explain 
how it affects cell motility and metastasis: CD44 and CD9.  
CD44is widely expressed, affects many cellular functions such as migration and adhesion, and 
the expression of some isoforms is linked to more invasive cancers. Martín-Villar et al. (2010) 
noted that CD44 and podoplanin were coordinately upregulated in aggressive cancer cell lines 
and subsequently found that they directly bind to one another. This interaction is dependent on 
correct glycosylation of the extracellular domain of podoplanin, and CD44 expression is required 
for podoplanin-induced cell migration [57].  
Additionally, Nakazawa et al. (2008) found that podoplanin directly interacts with the tetraspanin 
CD9 through transmembrane domains 1 and 2 of CD9. CD9 acts as a tumor suppressor in many 
cancers [73], and co-expression of CD9 and podoplanin resulted in a CD9-mediated decrease of 
Podoplanin-induced metastasis. CD9 inhibited podoplanin-mediated platelet aggregation without 
directly interfering with CLEC-2 binding of podoplanin [74]. This finding indicates that CD9 
potentially disrupts CLEC-2 multimerization, which is required for downstream signaling. These 
interactions provide some insight into how podoplanin can exert striking effects on actin 
cytoskeleton rearrangement, cell motility, and metastasis.  
The only known receptor for podoplanin is CLEC-2, a C-type lectin that is expressed by 
platelets, neutrophils, monocytes and dendritic cells (DCs) [75]. Glycosylation of T34 on 
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podoplanin is required for CLEC-2 binding of podoplanin. This amino acid resides in the 
platelet-aggregation stimulating (PLAG) domain, which is highly conserved between podoplanin 
homologues [76]. The effect of CLEC-2 engagement by podoplanin has been extensively studied 
in platelets; however, the effect of this interaction in podoplanin-expressing cells has not been 
addressed.  
Podoplanin interacts with galectin-8 on LECs, and this interaction is also dependent on 
podoplanin glycosylation [77]. Galectin-8 can have varying effects on adhesion depending on 
whether it is secreted or membrane-bound [45]; it seems that podoplanin binding to galectin-8 
may affect LECs adhesion, but additional studies are needed to fully elucidate the consequences 
of this interaction.  
Podoplanin also binds CCL21 with high affinity, and this interaction is also dependent on 
glycosylation of podoplanin [78]. This interaction has interesting implications for lymphocyte 
trafficking, as both LECs and FRCs express CCL21 to direct lymphocyte and DCs trafficking to 
the T zone of lymph nodes [79]. 
It has yet to be examined whether the above binding partners of podoplanin are cell-type specific 
or how interaction with one protein affects the binding of podoplanin to another interacting 
molecule. With the exception of the ERMs and CD44, it remains unclear whether podoplanin can 
bind to several of these proteins at one time or whether such interactions might be mutually 
exclusive. A more global understanding of these various interactions is critical to our overall 
understanding of podoplanin’s molecular functions and downstream signaling [45]. 
The cartoon below (Fig 9) represent the molecular interactions of podoplanin with its receptor 
CLEC-2 and the bindings with CD44 and CD9 [45].   
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Fig 9. Podoplanin binding. Podoplanin has its own receptor called CLEC-2, but is able to 
interact also with CD44 and CD9 as it is shown in the figure. 
 
Podoplanin: the joker protein  
In conclusion, podoplanin is a very interesting protein; it is expressed in a variety of different 
type of cells and in different context; a multitude of stimuli can drive podoplanin expression, 
including physiological differentiation factors in embryogenesis, potentially malignant factors 
such as pro-tumorigenic signaling pathways in cancer and pro-inflammatory cytokines in 
immune diseases or scar formation. podoplanin orchestrates the lymphatic and the immune 
system but also the malignancy of tumors. Different pathways controlling podoplanin 
upregulation or downregulation could result in the activation or inhibition of distinct downstream 
signaling pathways and therefore different cellular outcomes.  
There are still many unknown about podoplanin biology that remain to be answered and the 
future studies will provide critical insights into whether podoplanin can be used as a specific 
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marker for the diagnosis of “heathy” fibrosis and a target for the inhibition of inflammation 
besides that the metastasization. 
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Aims  
The majority of data examining the function and signaling pathways of podoplanin are from 
studies of podoplanin expression in lymphangiogenesis and cancer, while these studies certainly 
provide critical insight into cellular and molecular aspects of podoplanin biology, it is important 
to understand whether podoplanin functions similarly in non-pathological settings and in cell 
types where it isn’t naturally expressed.  
The aim of this project is to describe in a time dependent manner the expression of podoplanin in 
the scar formation after MI and analyze the co-expression of podoplanin with several markers 
that where not associated with the podoplanin expression before.  
The results of the study will provide terrific information regarding the biology of the healing 
heart after MI; a better understanding of the environment of the scar it will improve the feasible 
but modest therapy for the cardiac regeneration that are currently carried on.  
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Materials and Methods 
Myocardial infarction 
Experiments were conducted according to the NIH Guide for the Care and Use of Laboratory 
Animals and were approved by the Institutional Animal Care and Use Committee (IACUC). 
C57BL/6 and BDF1 Kit/GFP transgenic [80] mice were used interchangeably with identical 
results. Myocardial infarction (MI) was induced in female mice to reduce biological variability 
related to sex at 2-3 months of age as follows: animals were anesthetized with isoflurane 1.5% 
and ventilated, under sterile conditions the thorax was opened via the third costal space, the atrial 
appendage elevated, the left coronary artery located (S2, Fig 1), and a silk braided suture (6-0) 
was inserted and tightened around the vessel near the origin. Then, the chest was closed and 
pneumothorax reduced by negative pressure, and the animals were allowed to recover. Sham-
operated (SHAM) mice were subjected to an identical surgery procedure, with the exception that 
the suture was not tightened around the artery. Non-operated (NO) mice served as additional 
controls. At the time of sacrifice (S2, Fig 2), with the animals under deep anesthesia, bilateral 
thoracotomy was performed, the hearts were removed and either fixed and processed for 
histological analysis, or enzymatically digested [81] for single-cell assessment by flow-
cytometry, as described below.  
 
Immunohistochemistry of thin cardiac sections 
Hearts were perfused with 10% formalin, fixed and embedded in paraffin. Cardiac tissues were 
cut into 4 μm-thick sections. Following deparaffinization, rehydration, and heat-induced antigen 
retrieval (pH 6.0), samples were indirectly immunolabeled with commercially-available primary 
antibodies and corresponding fluorophore-conjugated secondary reagents; a complete list of 
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antibodies is provided in the S1 Table. Nuclei were counterstained with Hoechst 33342 (Life 
Technologies) or 4',6-diamidino-2-phenylindole dihydrochloride (DAPI; Sigma-Aldrich). 
Multiple sections from the hearts of at minimum 4 mice for each time point after MI and 3 mice 
per sham-operated group were examined, and representative micrographs are included in the 
figures. Images were acquired with Olympus FluoView FV100 laser scanning confocal 
microscope equipped with CCD camera (Bio-Rad), using 20X, 40X and 60X objectives. Optical 
sections (ΔZ= 0.5 to 1 µm) spanning the sample thickness were projected into a single plane for 
each color channel and merged using Adobe Photoshop (Adobe) or Imaris (Bitplane) software. 
Alternatively, the sections were blocked with hydrogen peroxide and indirectly immunolabeled 
with MOMA-2 or F4/80 antibodies (see S1 Table), followed by the development with 
diaminobenzidine (DAB) substrate kit (Vector) and counterstaining with hematoxylin and eosin 
(Poly Scientific R&D Corp.). Images were acquired using Olympus BX63 light microscope 
(Olympus Scientific Solutions Americas) with 20X and 40X objectives and assembled in Adobe 
Photoshop. Quantitative image analysis was performed with NIH ImageJ by scoring multiple 
imaging fields of 0.4 mm
2
 (20X objective) and 0.045 mm
2
 (60X objective) for every indicated 
time point after MI in the border zone (BZ) and remote area (RA) as follows: Podoplanin 
labeling was measured as % area above binary threshold of positive pixels out of total area 
populated by cells. Podoplanin co-labeling with LYVE-1, CD34 and VEGFR-3 was calculated 
using JACoP plugin to determine the degree of co-localization (ranging from the minimum of 
“0” to maximum of “1”) by Manders' overlap coefficient, i.e., the fraction of intensity in a 
channel of interest located in the pixels displaying above the threshold signal in the podoplanin 
channel. The occurrence of Prox-1, PDGFRα or PDGFRβ staining in podoplanin-positive cells 
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was assessed by counting the % of double-labeled cells from the total podoplanin-positive 
population in the imaging field.     
 
Immunolabeling of thick cardiac sections 
Hearts were perfused with 4% paraformaldehyde and stored at 4ºC. Sections of 75 to 250 µm 
were prepared using Leica VT1200 vibrating blade microtome (Leica Biosystems), and 
indirectly immunolabeled employing the reagents detailed in the S1 Table, and Alexa Fluor 647-
conjugated isolectin GS-IB4 (Life Technologies). Images were acquired with Olympus 
FluoView FV100 laser scanning confocal microscope using 10X and 20X objectives. Optical 
sections (ΔZ=1.5 to 2.5 µm) were projected into a single plane for each color channel, and 
merged using Adobe Photoshop or Imaris software. Representative micrographs are included in 
the figures. 
 
Flow-cytometry analysis of isolated cardiac cells 
Infarcted (MI) and sham-operated (SHAM) C57BL/6 mice were euthanized at 2 days after 
surgery, as described above. Non-operated (NO) age-matched animals were used as controls. 
The hearts were excised and extensively washed in phosphate buffered saline. The cardiac 
tissues were minced and subjected to repetitive rounds of enzymatic digestion with collagenase 
type 2 (Worthington Biochemical Corp.) until complete dissociation. Larger cells, such as 
mature myocytes, were precipitated, and the supernatants containing small cell populations were 
filtered through 40 µm cell strainers. High cell viability after isolation (~98%) was confirmed by 
flow-cytometry based on 7-AAD (BD Biosciences) exclusion. Samples were then either 
immediately stained with podoplanin and VEGFR-3, or fixed in 4% paraformaldehyde and 
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immunolabeled for podoplanin only, or podoplanin in conjunction with either LYVE-1, 
PECAM-1, CD34, Ly6C, CD11b, F4/80, PDGFRα or PDGFRβ. Prox-1 labeling was performed 
after the incubation of unfixed cells with podoplanin antibody, using fixation and 
permeabilization reagents from the transcription factor staining buffer set (affymetrix 
eBioscience) according to manufacturer’s instructions. The antibodies used for flow-cytometry 
are listed in the S1 Table. Non-immune normal goat, rabbit, syrian hamster and rat IgGs and 
isotype controls (detailed in the S1 Table) were employed as negative controls for the respective 
antigen-specific labeling. Similar procedures for mouse cardiac cell isolation and antibodies for 
the detection of podoplanin, LYVE-1, F4/80 or PDGFRα by flow-cytometry, were recently 
reported by other groups [82] [83]. Samples were acquired with BD FACSCantoII (BD 
Biosciences) and analyzed using FlowJo software (Tree Star Inc.). Single cells were gated using 
FSC-A/SSC-A followed by FSC-H/FSC-W and SSC-H/SSC-W in all experiments. 
Compensation settings, gating of positive populations and calculations of % positive cells were 
performed based on non-immune and isotype IgGs and fluorescence minus one controls. 
 
Statistical analysis 
Data were presented as values for individual mice and means. Statistical analysis was performed 
with two-tailed t-test or one-way ANOVA and Tukey’s post hoc test for multiple comparisons 
using GraphPad Prism (GraphPad Software).  
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Results 
Podoplanin in the infarcted heart: a time dependent expression 
In order to study the lymphangiogenesis and the appearance of the mesenchymal markers in 
acutely and chronically infarcted myocardium, we implemented immunohistochemical analysis 
of the tissue sections obtained from non-operated mouse hearts, as well as cardiac samples at 4 
and 8 hours (<1day), 2 days, 2 weeks and 1 month after coronary artery ligation, and sham-
operated animals.  
The established markers used for the identification of LVs are LYVE-1 and podoplanin and it is 
well-documented that the lymphangiogenesis in the infarcted heart is peaking with the 
development of fibrosis and commencement of scar maturation [41] [21] [84].
  
We observed that at the time of ischemia and consequential necrosis [41] [85], there was a slight 
decrease in podoplanin-labeled cells and structures in the necrotic area when compared to a 
corresponding myocardial region in non-operated hearts, as illustrated by 8 hours after MI, (Fig 
1A). Those findings are in agreement with previous ones in humans [41]. Surprisingly, at 2 days 
after MI, there was a more than a 6-fold increase in the podoplanin immunoreactivity in the 
infarct BZ relative to earlier time points after MI (< 1 day) or myocardial area remote to 
infarction (RA) (Figs 1A, 1B and 1E). As it is shown in the Fig 1A, 2 days after MI, all of the 
migratory cells that are recruited in the early stage of tissue granulation express podoplanin; 
interestingly podoplanin positive cells are located only in the BZ of the MI and they don’t 
infiltrate yet in the necrotic tissue suggesting that the immune cells recruited in the early stages 
of MI barely co-stain with podoplanin (S2, Fig 5). 
By flow-cytometry evaluation of isolated cardiac cells, we established that the frequency of 
podoplanin was relatively low in non-operated and sham-operated non-infarcted mouse hearts 
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(Fig 1C). In line with immunohistochemical findings on the podoplanin accumulation in the 
infarct BZ, by flow-cytometry analysis we determined that in the total infarcted hearts the 
occurrence of podoplanin-expressing cells versus non-operated and sham-operated counterparts 
was associated with more than three-fold increase (Fig 1C). 
Importantly, our funding are in line a recent study combining immunohistochemical and flow-
cytometry assessments of the mouse cardiac cellular composition, similarly reports that in 
homeostatic conditions, the podoplanin-positive cells are rare, constituting less than 5% of the 
myocardial endothelial cell population [83].  
Accordingly, during early inflammatory responses to tissue damage [85], there were no 
observable differences in the presence of LYVE-1-positive CLVs in proximity to the injured area 
(Fig 1E). In the infarcted myocardium, similarly to remote areas and sham controls, the LYVE-1 
labeling coincided with podoplanin almost exclusively in the vessel endothelium (Fig 1E-1H). In 
contrast, at the time of the appearance of podoplanin-positive cells at 2 days after MI, the co-
labeling of LYVE-1 with podoplanin in the infarct BZ was substantially diminished (Fig 1E and 
1F).  
We observed, shortly after MI, a robust accumulation of interstitial podoplanin-positive/LYVE-
1-negative cells in the infarct BZ (Fig 1E and 1F; 2 days), and a lesser extent podoplanin-
positive/LYVE-1-negative counterparts in the RA (Fig 1G; 2 days).  
Quantitatively, as compared to RA, in the infarct BZ there was more than a 30-fold decrease in 
the proportion of podoplanin-positive structures displaying the co-staining with LYVE-1 (Fig 1F, 
graph; 2 days). In support, flow-cytometry suggested that a much smaller fraction of podoplanin 
and LYVE-1 double-positive cells resided in the heart after MI compared to non-operated and 
sham-operated conditions (S2, Fig 3).  
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Similarly to the co-expression of podoplanin with LYVE-1also the co-labeling with a pan-
endothelial marker PECAM-1 was significantly reduced after MI in the cohorts of podoplanin-
presenting cells (S2, Fig 3); further demonstrating that a large share of podoplanin-bearing cells 
appearing after infarction in the myocardial interstitium did not display markers of mature 
endothelium.    
Subsequently, at 2 weeks after MI, at the maturation phase of wound healing, the density of 
podoplanin-labeled cells and CLVs was further elevated in the scar and BZ. We quantify an 
additional 1.7-fold increase in the podoplanin-labeled tissue area relative to 2 days, and a 10-fold 
rise relative to inflammatory stage (< 1 day) (Fig 1B and 1D-1F; 2 weeks), or the remote RA 
(Fig 1B and 1G ) and non-operated myocardium (Fig 1 and 2A; 2 weeks). 
In the healing scar, podoplanin immunoreactivity was apparent in LYVE-1-negative cell cords 
(Fig 1E and 1F; 2 weeks) and the proportion of podoplanin-positive cells co-labeled with LYVE-
1 at 2 weeks after MI was almost 15 times lower than in the RA (Fig 1F, graph; 2 weeks) 
suggesting that LYVE-1 is expressed in podoplanin positive cells only il CLVs and not in the 
interstitial podoplanin positive cells. T 
hese podoplanin-presenting LYVE-1-negative cells were aligned with the extracellular matrix 
(Fig 3A; 2 weeks) and formed capillary-like structures, which occasionally expressed CD34 (Fig 
3B). The co-labeling of podoplanin with CD34 was more readily detectable at the time of scar 
maturation at 2 weeks compared to an earlier stage of acute injury at 2 days (Fig 3B), with a 3-
fold increase in the co-localization coefficient relative to 2 days (Fig 3C; graph). Indeed, as 
evaluated by flow cytometry, shortly after MI there were no significant changes in the proportion 
of CD34-positive cells within podoplanin-presenting populations versus sham-operated controls 
(S2, Fig 3, Panel B; CD34). Intriguingly, the podoplanin-expressing cells also frequently 
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encircled the BVs in the fibrotic region and neighboring myocardium (Fig 1F, Fig 3D and 4D; 2 
weeks), which might point to their origin from perivascular cells or the cells recruited from 
circulation. 
At one month after MI, when the scar is well mature and the lost tissue is replaced by 
nonfunctional cells, the podoplanin labeling in the infarcted area and BZ remained high with no 
significant changes versus 2 weeks after MI (Fig 1B, 1D and 1F). As expected [41] [43], the 
presence of LYVE-1- and podoplanin-positive CLVs was prominent (Fig 1D-1F, 1H and Fig 2B; 
1 month), supporting the notion that lymphatics, once formed, persist in the scarred tissue [41] 
[42] [21] [86]. Simialr to that, the co-staining of podoplanin with CD34 was also increased in the 
maturing scar like it was at 2 weeks after MI (Fig 3B; 2 weeks  and Fig 3C; 1 month, and Fig 3C; 
graph), with an almsot 5-fold rise in podoplanin co-localization coefficient with CD34 relative to 
2 days (Fig 3C; graph). Correspondingly to the early stage of scar maturation, the podoplanin-
expressing population in the mature scar was dominated by the LYVE-1-negative multicellular 
assemblies (Fig 1E and 1F; 1 month), which were observed aligned with fibronectin deposits in 
the scar (Fig 3A; 1 month) and at the outline of small and large blood vessels (Fig 4; 1 month). 
In contrast, there was no such accumulation of the podoplanin-labeled cellular aggregates in the 
RA not affected by the infarction (Fig 1F, graph, RA and Fig 1G; 1 month). Quantitatively, there 
was more than a 10-fold decrease in the podoplanin and LYVE-1 co-localization in the chronic 
scar and BZ compared to RA (Fig 1F; 1 month). Collectively, these findings point to a 
correlation between the presence of podoplanin-expressing LYVE-1-negative cells at different 
stages of cardiac healing and the development of CLVs and fibrosis after MI. 
Of interest, the growth of CLVs and appearance of podoplanin-positive interstitial cells were not 
detected in the sham-operated animals (Fig 1H; 1 month SHAM). Likewise, there were no 
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significant differences in the frequency of podoplanin between the sham- and non-operated 
hearts at 2 days after surgery (Fig 1C). These data underscore a specific effect of the MI-induced 
injury on the podoplanin expression and lymphangiogenesis.  
 
40 
 
 
 
41 
 
 
42 
 
 
43 
 
 
44 
 
Fig 1. Podoplanin expression in the infarcted and non-infarcted hearts. (A) Thin cardiac 
sections from non-operated (NO) mice and animals at the indicated times after MI were 
indirectly immunolabeled with podoplanin (red). Nuclei, blue. Areas neighboring the necrotic 
myocardium are shown for the infarcted hearts. Note the increase in podoplanin 
immunoreactivity at 2 days after MI. (B) Quantitative image analysis of the changes in 
podoplanin immunolabeling in thin cardiac sections in the infarcted myocardium at the indicated 
times after MI. RA, remote area. Data represent mean and SD of % area stained with podoplanin; 
n=6-10 image fields per group. By one-way ANOVA, *P < 0.02 for 2 days vs. RA, 2 weeks, or 1 
month; **P = 0.0017 for 2 days vs. <1 day; ***P < 0.0001 for RA vs. 2 weeks or 1 month and 
for <1 day vs. 2 weeks or 1 month; ns, non-significant for < 1 day vs RA, and for 1 month vs. 2 
weeks. (C) Flow-cytometry analysis of the frequency of podoplanin-positive cells in the hearts of 
non-operated (NO), and the sham-operated (SHAM) and infarcted (MI) mice at 2 days after 
surgery. Graph depicting data from individual animals (upper row) and representative flow-
cytometry scatterplots (lower row) are shown. n=10-20 animals per treatment; mean values are 
represented by the red line on the graph. By one-way ANOVA, *P < 0.0001 for MI vs. SHAM or 
NO; ns, not significant for SHAM vs NO. (D-H) Thin cardiac sections obtained at the indicated 
times after MI were indirectly immunolabeled with antibodies that recognize podoplanin (D-H; 
red), LYVE-1 (E-H; green), and PECAM-1 (E and H; grey). Nuclei, blue. Corresponding single 
channel images (E-H) are included in S2 Fig 1. Areas affected by ischemia are depicted in D-F; 
Remote area (RA) is shown in G. SHAM, sham-operated in H. In F, the arrowheads in 
representative images (upper panels) point to the examples of podoplanin-positive LYVE-1 
negative cells. Note the accumulation of LYVE-1 positive CLVs (red and green) as well as 
podoplanin-expressing cells lacking the LYVE-1 labeling (red only) in the infarcted myocardium 
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as opposed to RA and SHAM. Quantitative image analysis (lower panel) of the podoplanin co-
labeling with LYVE-1 is included in the graph. Data represent mean and SD of the co-
localization coefficient measured at indicated times after MI and the remote area (RA); n=5-10 
image fields per group. By one-way ANOVA, *P < 0.0001 for RA vs. 2 days, 2 weeks or 1 
month; no significant changes between 2 days and 2 weeks and 1 month.       
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Fig 2. CLVs in the forming and mature scar. Thick cardiac sections were indirectly 
immunolabeled with the mix of LYVE-1 and podoplanin antibodies (A,B; red) and α-SMA 
antibody (B; grey), and co-stained with isolectin GS-IB4 (A,B; green). NO, non-operated. Time 
after MI is indicated. Corresponding single channel images are included in S2 Fig 2. CLVs are 
recognized by the staining with podoplanin and LYVE-1. In A, note the changes in the 
abundance and distribution of the vessels and LYVE-1 and podoplanin immunolabeled cells at 
different stages of infarct healing. In B, α-SMA-positive cells are apparent in the fibrotic tissue 
and the coating of large vessels. 
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Fig 3. Phenotype of podoplanin-positive cells in the fibrotic tissue. Thin cardiac sections were 
indirectly immunolabeled with antibodies that recognize podoplanin (red) and either fibronectin 
and vimentin (A; green and grey, respectively), VEGFR-2 and CD34 (B and C; green and grey, 
respectively), or α-SMA (D; grey). Nuclei, blue. Time after MI is indicated. Areas in rectangles 
are shown at higher magnifications in the adjacent images for each color channel. Note that 
vimentin (A) or α-SMA (D) labeling is rarely detectable in podoplanin-expressing cells 
(examples are pointed by yellow arrowheads). In B and C, the podoplanin-presenting cells show 
minimal VEGFR-2 labeling. At 2 days after MI, the podoplanin-bearing cells mostly do not co-
stain with CD34 (exemplified by yellow arrowheads). Starting 2 weeks after MI, the CD34 
staining is present in irregular capillary-like structures (examples are indicated by white arrows). 
In C, quantitative image analysis demonstrating changes in the podoplanin co-labeling with 
CD34 at indicated times after MI is included in the graph (lower panel). Data represent mean and 
SD of the co-localization coefficient; n=5-6 image fields per group. By one-way ANOVA, *P < 
0.02 for 2 weeks vs. 2 days; **P < 0.0001 for 1 month vs. 2 days; ns, not-significant 1 month vs. 
2 weeks. 
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Fig 4. Perivascular localization of the podoplanin-expressing cells. Thin cardiac sections 
were indirectly immunolabeled with podoplanin (red) and VEGFR-2 (green) antibodies. Nuclei, 
blue. Time after MI is indicated. Areas in rectangles are shown at a higher magnification in the 
adjacent images for each color channel and merged. Note the podoplanin-positive cells 
encircling the VEGFR-2-labeled BVs.  
 
Podoplanin-positive cell population manifest a variable expression of the lymphatic 
endothelial cell markers Prox-1 and VEGFR-3 in the heart 
In order to assess the lymphangiogenic potential of the podoplanin-bearing cells in the infarcted 
myocardium, we evaluated the presence of a lymphatic endothelial cell-specific transcription 
factor Prox-1 [87] [88] in this population. We noted that along with the expected localization in 
the nuclei of the endothelium of CLVs (Fig 5A-5C; arrows), Prox-1 staining was detectable also 
in the podoplanin-positive cells not organized into vessel-like structures (Fig 5A-5C; white 
arrowheads) at different times after MI.  Quantitatively, as detected by flow-cytometry the 
frequency of Prox-1 expression in podoplanin-positive cells was diminished at 2 days after MI as 
compared to sham-operated hearts (S2, Fig 3 Panel B; Prox-1). These data are consistent with the 
findings on a lower presence of LYVE-1 and PECAM-1 in the podoplanin-expressing cell 
cohorts, thus validating the theory that a large proportion of podoplanin-bearing cells appearing 
acutely after injury do not possess differentiated lymphatic endothelial  phenotype.  
The occurrence of Prox-1 in the infarcted myocardium was generally high at the later stages of 
wound repair (Fig 5B, 5C; 2 weeks and 1 month) confirming that the neo lymphangiogenesis is 
required for the scar maturation and the resolution of inflammation. However, there was no 
direct correlation between the incidences of podoplanin and Prox-1 in these cell cohorts (Fig 5B 
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and 5C; yellow arrowheads). Despite a major rise in the abundance of podoplanin-presenting 
cells in the scarred tissue (Fig 1B and 1D-1F; 2 days versus 2 weeks and 1 month), we observed 
that the percentage of podoplanin-labeled Prox-1-positive cells in the injured area remained 
similar at all the time points after MI (Fig 5C; graph), supporting the notion that many of the 
newly-appearing podoplanin-expressing cells in the fibrotic area are Prox-1 negative and that 
Prox-1 is closely correlated only with the lymphatic lineage. 
VEGFR-3 is another characteristic marker of the lymphatic endothelial cell activation and 
differentiation [88, 89]. The expression of the VEGFR3 was discontinuous compared with 
constant presence of LYVE-1 in the CLVs (Fig 5E-5G; white arrows) of the infarcted 
myocardium, and only occasionally found in the podoplanin-positive cells populating the infarct 
BZ shortly after MI (Fig 5E and 5G; 2 days). By flow-cytometry, the frequency of VEGFR-3 co-
staining with podoplanin was not affected by acute myocardial injury as compared to non-
operated and sham-operated animals (S2, Fig 3 Panel B). The level of VEGFR-3 
immunolabeling was augmented at the later phases of infarct healing at 2 weeks and 1 month, 
and the co-staining of VEGFR-3 with podoplanin was intensified at these stages (Fig 5F and 5G; 
white arrowheads). These data suggest that VEGFR3 is highly expressed in the CLVs cells only 
when the lymphatic vessel is mature and well formed, this theory is confirmed quantitatively: 
more than a 5-fold elevation in the co-localization of podoplanin with VEGFR-3 was found at 
the time of scar formation and maturation relative to 2 days after MI (Fig 5G; graph). Yet, 
VEGFR-3-expression was frequently lacking in podoplanin-presenting cells (Fig 5F and 5G; 
yellow arrowheads).  
Our analysis, along with the quantitative data, show that the appearance of Prox-1 or VEGFR-3 
in a subset of podoplanin-expressing cells suggests their commitment to the LECs fate.  
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At the same time, the absence of lymphendothelial epitopes in a large group of podoplanin-
positive cells might signify an alternative differentiation pathway, or, most importantly that 
different type of cells that are recruited for the granulation and the scar formation after MI 
express podoplanin in response to the inflammation similarly to cancer cells; it is very important 
to keep in mind that podoplanin is involved in cell migration and the receptor C-LEC2 is highly 
expressed in immune cells.  
In contrast to VEGFR-3, the presence of VEGFR-2, a very well-known marker of endothelial 
cells, was rarely detected in podoplanin-bearing interstitial cells and CLVs in the infarcted heart 
(Fig 3B, 3C and Fig 4). This is in agreement with previous reports demonstrating that in the 
mouse, VEGFR-2 is restricted to the activated blood endothelium and not to the lymphatic ones 
[90].  
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Fig 5. Variable expression of Prox-1 and VEGFR-3 in podoplanin-positive cells in the 
infarcted heart. Thin cardiac sections were indirectly immunolabeled with antibodies that 
recognize podoplanin (red) and either Prox-1 (A-D; green) or VEGFR-3 (E-H; green). Nuclei, 
blue. Time after MI is indicated. Areas in rectangles are shown in the adjacent images for each 
color channel and merged. White arrows indicate examples of Prox-1 or VEGFR-3 labeling in 
the lymphatic endothelial cells of CLVs, and white arrowheads point to the examples of Prox-1 
or VEGFR-3 staining in podoplanin-expressing interstitial cells. Yellow arrowheads exemplify 
instances of podoplanin-positive cells in which Prox-1 or VEGFR-3 expression was 
undetectable. Note the consistent detection of Prox-1 and VEGFR-3 in CLVs, and the 
heterogeneity in Prox-1 and VEGFR-3 labeling intensity in podoplanin-stained cells not 
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organized into vessels. In C, quantitative image analysis (graph, lower panel) of the fraction of 
podoplanin-expressing cells co-labeled with Prox-1 is shown at indicated times after MI. Data 
represent mean and SD of the % double-positive cells out of all podoplanin-positive cells in the 
imaging field; n=6-9 image fields per group. By one-way ANOVA, no significant changes 
between were groups. In G, quantitative image analysis (graph, lower panel) of the podoplanin 
co-labeling with VEGFR-3 is shown. Data represent mean and SD of the co-localization 
coefficient measured at indicated times after MI; n=4-7 image fields per group. By one-way 
ANOVA, **P = 0.002 for 2 weeks vs. 2 days; *P =  0.009 for 1 month vs. 2 days; ns, not-
significant 1 month vs. 2 weeks. 
 
Podoplanin-positive cell population show a time dependent positivity to mesenchymal markers 
PDGFRα and PDGFRβ 
In the infarcted myocardium, the heightened expression of PDGFRα, PDGFRβ and their PDGF 
ligands coincides with angiogenesis and inflammatory and fibrogenic responses, indicating a role 
in wound repair processes [91] [92]. We found, by flow-cytometry analysis of all of the small 
cardiac cells isolated from acutely infarcted hearts, that the podoplanin-presenting cells in the 
infarcted heart were distinctly PDGFRα-positive (S2, Fig 4). Those data were confirmed by the 
immunohistochemistry assessment of myocardium at the different times after MI (Fig 6A-6C; 
white arrowheads, and Fig 6C; graph). Since PDGFRα expression is associated with the 
properties of immature mesenchymal cells [93, 94], the concordance of PDGFRα and podoplanin 
staining suggests that cardiac podoplanin-positive cells contain a population with progenitor cell 
capabilities.  
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Similarly to the PDGFRα, the PDGFRβ is a marker of pericytes and perivascular progenitor cells 
cells with endothelial and fibrogenic potential [95], but, unlike PDGFRα, the presence of 
PDGFRβ was infrequent in the podoplanin-presenting cells early after MI (Fig 6E; 2 days, 
yellow arrowheads, Fig 6G; graph,). However, we noticed that the level of PDGFRβ expression 
and co-staining with podoplanin were strongly elevated at the later stages of infarct healing and 
in the mature scar (Fig 6F and 6G; 2 weeks and 1 month, white arrowheads), reaching 
approximately 100% co-labeling of podoplanin-positive cells with PDGFRβ (Fig 6E, graph; 2 
weeks and 1 month).  
Interestingly, in the infarcted myocardium, PDGFRβ labeling was abundant not only in the 
CLVs but also in the BVs (Fig 6I).  A recent lineage-tracing analysis shows that PDGFRβ-
positive endothelium contributes to the CLV formation during embryonal development [96], 
implying that upon severe tissue injury, blood endothelial cells acquire the lymphatic endothelial 
cell phenotype. Such endothelial cell plasticity has been previously described in cultured cells 
and for the tumor vasculature [97, 98]. We report, confirming the literature, that Prox-1 is 
expressed in the nuclei of podoplanin-negative cells of the BVs (Fig 6I; arrows).  
Although the expression of PDGFR α or β is often related to the fibrogenic behavior and 
associated with the myofibroblast phenotype of cells [93] [99] [100], we found that the 
podoplanin-positive populations in the scar occasionally exhibited fibroblast markers vimentin 
(Fig 3A; yellow arrowheads) or a myofibroblast protein α-SMA (Fig 3D; yellow arrowheads). 
This data suggests that the podoplanin is not a marker of maturing fibrogenic cells. 
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Fig 6. Expression of PDGFRα and PDGFRβ in podoplanin-positive populations. Thin 
cardiac sections were indirectly immunolabeled with podoplanin (red) and either PDGFRα (A-D; 
green), PDGFRβ (E-H; green), or PDGFRβ and Prox-1 (I; green and grey, respectively) 
antibodies. Nuclei, blue. In A-H, time after MI is indicated. Areas in rectangles are shown in the 
adjacent images for each color channel and merged. In A-D, podoplanin is frequently co-stained 
with PDGFRα at every time point; examples are indicated by white arrowheads. In E, 
podoplanin-positive cells are mostly PDGFRβ-negative, as exemplified by yellow arrowheads. In 
F-H, PDGFRβ distinctly co-stained with podoplanin. In C and G, quantitative image analysis 
(graphs, lower panels) of the fraction of podoplanin-expressing cells co-labeled with PDGFRα 
(C) and PDGFRβ (G) are shown at indicated times after MI. Data represent mean and SD of 
the % double-positive cells out of total podoplanin-positive cells; n=5 image fields per group. By 
one-way ANOVA for PDGFRβ, *P < 0.0001 for 2 days vs. 2 weeks or 1 month; ns, not-
significant for 1 month vs. 2 weeks. In I, arrows point to the examples of Prox-1 staining in the 
nuclei of PDGFRβ-positive podoplanin-negative BVs. 
 
The role of inflammation in the recruitment of podoplanin-expressing cells 
Inflammation-induced lymphangiogenesis is a well-established phenomenon implicated in 
wound healing responses sine the lymphangiogenesis is needed for the resolution of the 
inflammation and the return of the immune cells back to the circulation [86] [101] [102].  
In the present study we also examined few cases of MI with higher inflammation, like 
granulomas. Granuloma is a form of inflammatory reaction described for several diseases. It is 
noted that nodules of granulomas in different tissues are characterized by the presence of 
podoplanin-positive cells and LVs of heterogeneous and atypical morphology, which frequently 
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express PDGFRβ [90, 95] [103] [104], resembling the podoplanin-labeled cells in the chronically 
infarcted heart (Fig 6G; 1 month).  
Few experimental mice developed granulomas near to the insertion of a suture thread within the 
myocardium.  
We found a high density of podoplanin labeling in the granuloma nodules in the heart (Fig 1D-
1F, and Fig 3A and 3C; 1 month/granuloma), but not in the RA of the same samples (Fig 1G; 1 
month/granuloma). Importantly, the frequency of podoplanin-positive cells that express Prox-1 
or VEGFR-3 was increased in the scar and BZ in the cardiac samples with MI and granulomas as 
compared to MI only (Fig 5C and 5G; 1 month and Fig 5D and 5H; 1month/granuloma), as 
expected in a highly inflammatory environment.  
Although the lymphangiogenic responses in the infarcted myocardium with granulomas were 
apparently amplified relative to MI only (Fig 1D), the phenotypic features of podoplanin-labeled 
cells in the hearts with granulomas, including vascular markers (Fig 3C; 1 month/granuloma) and 
PDGFRα and PDGFRβ (Fig 6D and 6H, 1month/granuloma), were similar to the ones observed 
in the absence of granuloma (Fig 3C and Fig 6C and 6G; 1 month). This suggests that the surge 
in podoplanin expression following acute MI is at least partly driven by inflammation.  
The inflammatory reaction to myocardial injury is evident by a time-dependent accumulation of 
immune cells, including macrophages. In murine embryos and pathological conditions, cells that 
exhibit traits of macrophages display characteristics of lymphatic endothelial cells and localize in 
the regions of lymphatic vessel growth, serving as a source of lymphangiogenic factors, and 
potentially integrating into newly-formed vessels [105] [106]. We did not detect the presence of 
monocyte-macrophage markers MOMA-2 (Fig 7A), F4/80 (Fig 7B), or CD11b and Ly6C (S2, 
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Fig 5) in the infarcted myocardial areas that were characterized by the accumulation of 
podoplanin-positive cells (Fig 1).  
In order to confirm that podoplanin is partially expressed by the immune cells, we performed a 
flow-cytometry analysis. As previously said, the immune cells show the ligands for podoplanin 
and barely the podoplanin itself. 
By flow-cytometry we documented that at 2 days after MI on average only 20% of podoplanin-
positive cells in the infarcted heart were labeled with either F4/80, CD11b (Fig 7C) or Ly6C (S2, 
Fig1; Panel 5) antibodies. These data indicate that the podoplanin-expressing pools in the heart 
in majority do not correspond to maturing macrophages, although, as discussed below, their 
hematopoietic origin cannot be excluded [107].  
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Fig 7. Low expression of monocyte-macrophage markers in the populations of podoplanin-
positive cells in the infarcted myocardium. (A,B) Thin cardiac sections were indirectly 
immunolabeled with MOMA-2 (A) or F4/80 (B) antibodies and counterstained with hematoxylin 
and eosin. Time after MI is indicated. Spleen sections were included as positive controls. Areas 
in rectangles with the corresponding numbers are shown at a higher magnification in the adjacent 
insets. Note the presence of cells immunoreactive for MOMA-2 or F4/80 (arrows) in the 
inflamed epicardium (2 days, insets 2), myocardial interstitium (2 weeks, insets 2) and spleen, 
but not in the BZ of necrotic myocardium (2 days, insets 1) or the maturing scar (2 weeks, insets 
1). (C) Flow-cytometry analysis of the F4/80 or CD11b expression in the podoplanin-positive 
cohorts populating the hearts of non-infarcted (NO), sham-operated (SHAM) and infarcted (MI) 
mice at 2 days after surgery. Graphs displaying individual values and the respective means (left), 
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as well as representative scatterplots (right) are shown. Data represent frequency of double-
positive cells within podoplanin-labeled populations (calculated as % cells in gate 2 out of the 
sum of cells in gate 1 and gate 2). 
 
Discussion  
In the present work we studied the healing process and scar formation in the heart using MI as a 
model of the lymphangiogenic and fibrogenic responses. We identified a hitherto unconsidered 
glycol protein named podoplanin as a master regulator of different stages of myocardial wound 
repair after infarction. 
We established that shortly after MI, at the time corresponding to the later phases of granulation 
of the necrotic tissue in the infarcted myocardium, the well-defined lymphatic marker 
podoplanin was expressed more than six-fold in the areas neighboring the infarction as compared 
to remote area, and we fund a three-fold increase in the frequency of podoplanin-positive cells in 
the whole heart relative to non-operated and sham operated controls.  
These newly-appearing podoplanin-presenting cells not organized into vessels-like structures 
were predominantly LYVE-1-negative and exhibited a heterogeneous phenotype in terms of 
various markers of mesenchymal and endothelial fates.  
We characterized the podoplanin cohort of cells by co-immunolabeling with several markers in a 
time dependent manner. 
The immunolabeling profile of podoplanin-expressing cells at the different stages of infarct 
repair is summarized in Table1. 
The presence of podoplanin-bearing cells was mainly prominent in the areas of future 
lymphangiogenesis at the infarct BZ; furthermore the abundance of podoplanin was elevated 
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almost two-fold in the healing and maturing scars but not the RA, concomitantly with the 
previously reported increase in LYVE-1 and VEGFR-3-positive CLVs [41] [43] and the buildup 
of fibronectin deposits [86] [87]. 
The fate of podoplanin positive cells it would have been predictable based on the knowledge 
already present in literature, but a very detail observation showed that cells positive to 
podoplanin were not lineaged only into the lymphatic fate. 
 Of note, the expansion of podoplanin-positive compartment and CLVs was not noticeable in the 
myocardium of sham-operated animals. We also establish a detailed characterization of the 
accumulation of podoplanin-labeled multicellular assemblies intensified in vicinity of 
myocardial granuloma nodules, exhibiting similarities to encapsulating peritoneal sclerosis [103] 
and pulmonary sarcoid granulomas [104].  
Based on our observation the inflammatory processes might play a significant role in the 
recruitment of podoplanin-bearing LYVE-1-negative cells to the site of myocardial repair or the 
activation of podoplanin expression in responsive cell cohorts, not only for the 
lymphangiogenesis but also for the renovation of the necrotic tissue.  
Podoplanin is expressed in a variety of different type of cells and in different context; a multitude 
of stimuli can drive podoplanin expression, including physiological differentiation factors in 
embryogenesis, potentially malignant factors such as pro-tumorigenic signaling pathways in 
cancer and pro-inflammatory cytokines in immune diseases, so, we cannot exclude that the scar 
formation environment it stimuli the over expression of podoplanin.  
Indeed, inflammation and neoplastic growth alter the podoplanin level in various cell types, 
impacting their differentiation status and migratory behavior [108] [109]. In addition, homing of 
circulating cells is proposed to contribute to the LVs formation under inflammatory conditions 
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[107] [110], with evidence that rare bone marrow-derived podoplanin-positive cells express 
Prox-1 and function as lymphatic endothelial progenitors [110].  
Although the podoplanin-mediated signaling pathway is not sufficiently understood, the 
expression of podoplanin is cognate toLECs; and inflammatory lymphangiogenesis is attenuated 
if podoplanin activity is lacking [28] [111]. Podoplanin deficiency impairs cardiac development 
[28], while continuous expression of podoplanin into adulthood is required to maintain 
functional lymphatic vasculature [108] [112]. 
 We detected the presence of canonical lymphendothelial markers Prox-1 and VEGFR-3 within 
the cohort of podoplanin-positive LYVE-1-negative cells (Table 1), which might be indicative of 
their differentiation into LECs of CLVs. We confirmed that Prox-1 is required for the 
transcription and that VEGFR3 is essential for the lymphatic vessel formation. 
Additionally, a hematoendothelial epitope CD34 was observed in podoplanin-presenting cells, 
and its expression was augmented with time after MI (Table 1). CD34 labeling may signify a 
hematopoietic origin of these cells, or, an endothelial progenitor one. Moreover, CD34 
upregulation distinguishes lymphatic endothelium in tumors [113]. Hence the presence of CD34 
in podoplanin-expressing cells and vessels of the chronically infarcted heart might point to their 
activated diseased state.        
Nevertheless, a considerable fraction of the podoplanin-presenting cells, which was seemingly 
indistinguishable from the above cell group in terms of morphology [108] and tissue location, 
did not exhibit any of the markers associated with endothelial commitment, respectively: Prox-1, 
VEGFR-3, CD34 and PECAM-1.  
These findings imply that podoplanin-positive compartment in the infarcted myocardium 
constitutes an inhomogeneous population, consisting of cells with a variable potency to adopt the 
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lymphatic endothelial or other cell fates. For instance, it has been documented that interstitial 
stroma cells acquire podoplanin expression after organ injury and in pathological conditions 
accompanied by fibrosis in the skin, skeletal muscle and peritoneum [114] [105] [115].  
Importantly, we documented for the first time that a mesenchymal marker PDGFRα was highly 
represented in podoplanin-positive cells in the heart (Table 1). Cells positive to PDGFRα are 
proposed to function as mesenchymal progenitors, which in response to injury and inflammation 
reveal plasticity regarding their ability to differentiate into endothelium or act as profibrotic cells 
[93] [116] [99] [100]. The predisposition towards the fibrogenic phenotype is influenced by the 
presence of pathologies and with aging, and can be antagonized to reduce scarring and improve 
angiogenesis [117]. Thus, the high expression of PDGFRα, along with irregular occurrences of 
Prox-1 and VEGFR-3 (Table 1), might signify an alternative ability of podoplanin-bearing cells 
to generate LECs or fibroblasts, impacting the outcome of the myocardial repair process. 
Likewise, in the human liver, podoplanin discriminates disparate categories of progenitor and 
stromal cell subsets, which display cell fate plasticity, population growth, and alterations in the 
relative distribution under conditions of chronic inflammation and fibrosis [118]. 
PDGFRβ have been also associated with podoplanin, in fact inflamed and fibrotic tissues are 
characterized by the abundance of podoplanin-presenting cells of mesenchymal morphology, 
which often co-express PDGFRβ [95] [103] [104]; PDGFRβ is also linked to the fibrogenic 
activity of mural cells [100] [119]. Of interest, granuloma nodules in the heart showed similar 
accumulation of podoplanin and PDGFRβ co-presenting cells. In the infarcted myocardium with 
no granulomas, the high occurrence of podoplanin in PDGFRβ -bearing cells was apparent as 
well, albeit at the later stages of wound repair, concomitantly with the scar development (Table 
1). Disruption of the PDGFRβ signaling impairs post-MI angiogenesis and BV maturation, and 
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decreases collagen content in the wound, destabilizing the scar [120]. Therefore, the acquisition 
of podoplanin by PDGFRβ-positive cells in the chronically infarcted myocardium might reflect 
their active role in lymphangiogenesis, fibrotic responses and scar maintenance.  
Yet, the markers of fibroblast, such as vimentin and α-SMA, were rarely detected in podoplanin-
positive cells residing in the fibrotic areas (Table 1); based on the observation on the podoplanin 
expression in PDGFRα and PDGFRβ cells, we can extrapolate that podoplanin is expressed 
mostly in progenitor cells that later can be positive to vimentin or α-SMA with a full 
transformation into myofibroblasts. Indeed, analogous type of PDGFRα-positive progenitors, 
which acquire fibrogenic behavior due to a partial endothelial-mesenchymal transition but do not 
become myofibroblasts, has been reported in the injured muscle [93] [99]. 
The growth of lymphatic network in adult organs is believed to occur as a result of the 
proliferative expansion and/or sprouting of new LVs from pre-existing lymphatics [86] [101] 
[113]. These processes are seemingly conditioned by the type of stimulus: whereas VEGFR-2 
activation mainly induces vessel enlargement, VEGFR-3 signaling promotes sprouting [121] 
[89]. Notably, VEGFRs, as well as VEGF-C and -D ligands, are up-regulated in the peri-
infarcted region [41] [96] [21] [122]. Administration of a selective VEGFR-3 agonist to the 
infarcted heart induces strong and sustained lymphangiogenesis [96] [21]. VEGFR-3 signaling is 
enhanced by mechanical stretch [115], which may explain the development of the lymphatic 
vasculature when interstitial pressure is elevated. Intriguingly, activation of podoplanin on the 
lymph node reticular cells diminishes their contractility, altering organ shape and stiffness under 
inflammatory conditions [123]. Thus, podoplanin-positive cells in the infarcted myocardium 
might affect local tissue tension, indirectly impacting VEGFR-3-stimulated CLV growth, 
extracellular matrix deposition and scar remodeling. 
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Table 1. Summary of the observed immunolabeling profile of podoplanin-expressing cells 
at different stages of infarct repair 
(a), (b), (c), (d)
. 
 
(a)
 – designates that < 20% cells are co-labeled 
(b)
 -/+ designates that 20-50% cells are co-labeled 
(c)
 + designates that > 50% cells are co-labeled 
(d)
 ++ designates that all the cells are co-labeled 
§
no scar was formed at 2 days 
(*) 
interstitial and perivascular cells were seldom detected in the RA 
(1)
interst. and perivas. designates interstitial and perivascular cells; comparison pertanting to 
interstitial and perivascular podoplanin-positive cells are shaded 
(2)
lymph. vessels designates cells organized in LVs  
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Conclusion 
 
In conclusion, our detailed spatiotemporal analysis of the acutely and chronically infarcted 
myocardium shows that podoplanin expression in the heart identifies structurally and 
phenotypically diverse cell categories, displaying epitopes of fibrogenic and endothelial 
commitment. The majority of data examining the function and signaling pathways of podoplanin 
are from studies of podoplanin expression in lymphangiogenesis and cancer, while these studies 
certainly provide critical insight into cellular and molecular aspects of podoplanin biology, it is 
important to understand whether podoplanin functions similarly in non-pathological settings and 
in cell types where it isn’t naturally expressed.  
Below, the cartoon represents a “summarized” scar tissue. Has it is shown in the histological 
staining, a mature scar is composed by disperse or perivascular LVs (in blue) of different size, 
capillaries (light purple), small and big arterioles (endothelial cell lining in purple and smooth 
muscle cells in deep blue) and a cohorts of cells that are scatter along the ECM. We 
characterized these cells, and although they have different origin or belong to different lineage 
they have in common the expression of podoplanin (red lining). In the cartoon all the cells that 
are positive to podoplanin have a red lining and in order to distinguish the populations they are 
exemplified with different colors: the lymphatic endothelial cells are represented in light blue, 
the mesenchymal progenitors in green or yellow and the endothelial progenitors in orange or 
yellow as well. In grey are labeled the immune cells. The colors and the characteristics are 
summarized in the legend. 
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Further studies are warranted to determine whether cells with lymphangiogenic or profibrotic 
potentials can be recognized within the heterogeneous podoplanin-presenting populations and 
utilized to promote the CLV growth and attenuate the development of fibrosis after MI.  
There are still many unknown about podoplanin biology that remain to be answered and the 
future studies will provide critical insights into whether podoplanin can be used as a specific 
marker for the diagnosis of “heathy” fibrosis and a target for the inhibition of inflammation 
besides that the metastasization. 
The results of our study provided terrific information regarding the biology of the healing heart 
after MI; a better understanding of the environment of the scar it will improve the feasible but 
modest therapy for the cardiac regeneration that are currently carried on.  
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Supporting Information 
S1 Table. Primary and secondary reagents employed for immunolabeling, light 
microscopy, and flow-cytometry 
 
Primary Antibodies 
Antigen Manufacturer Catalogue number Host species Applications 
podoplanin RnD Systems AF3244 goat IHC
(*)
, FC
(*)
 
podoplanin Thermo Fisher Scientific MA5-1613 syrian hamster IHC
(*)
 
APC
(§)
-podoplanin BioLegend 127409 syrian hamster FC
(*)
 
LYVE-1 RnD Systems AF2125 goat IHC
(*)
 
LYVE-1 Abcam ab14917 rabbit IHC
(*)
, FC
(*)
 
PECAM-1 RnD Systems AF3628 goat IHC
(*)
 
PECAM-1 BD Pharmingen 553370 rat FC
(*)
 
Prox-1 Abcam ab37128 rabbit IHC
(*)
,FC
(*)
 
Prox-1 Millipore AB5475 rabbit FC
(*)
 
PDGFRα Cell Signaling Technology 3174 rabbit IHC(*) 
PE
(§)
-PDGFRα BioLegend 135905 rat FC(*) 
PDGFRα RnD Systems AF1062 goat FC(*) 
PDGFRβ Cell Signaling Technology 3169 rabbit IHC(*) 
PDGFRβ Abcam ab51876 rat IHC(*) 
PE
(§)
-PDGFRβ BioLegend 136005 rat FC(*) 
PDGFRβ RnD Systems AF1042 goat FC(*) 
VEGFR-3 BD Biosciences 552857 rat IHC
(*)
 
PE
(§)
-VEGFR-3 Miltenyi Biotech 130-102-216 rat FC
(*)
 
VEGFR-2 Cell Signaling Technology 9698 rabbit IHC
(*)
 
CD34 BioLegend 119301 rat IHC
(*)
 
PE
(§)
-CD34 BD Pharmingen 551387 rat FC
(*)
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vimentin Sigma-Aldrich V2258 mouse IHC
(*)
 
fibronectin Abcam ab2413 rabbit IHC
(*)
 
α-SMA Sigma-Aldrich A2547 mouse IHC(*) 
MOMA-2 AbD Serotec MCA519G rat IHC
(*)
 
F4/80 AbD Serotec MCA497GA rat IHC
(*)
 
PE
(§)
-F4/80 BioLegend 123109 rat FC
(*)
 
CD11b AbD Serotec MCA74GA rat IHC
(*)
, FC
(*)
 
Ly6C AbD Serotec MCA2389T rat IHC
(*)
 
Alexa Fluor 647-Ly6C BioLegend 128009 rat FC
(*)
 
 
Non-immune IgGs 
Description Manufacturer Catalogue number Host species Applications 
Normal IgG control RnD Systems AB-108-C goat FC
(*)
 
Normal IgG control RnD Systems AB-105-C rabbit FC
(*)
 
APC
(§)
-IgG control BioLegend 402012 syrian hamster FC
(*)
 
PE
(§)
-IgG2a control BioLegend 400507 rat FC
(*)
 
PE
(§)
-IgG2a control BD Pharmingen 553930 rat FC
(*)
 
IgG2a control BioLegend 400501 rat FC
(*)
 
APC
(§)
-IgG2a control eBioscience 17-432181 rat FC
(*)
 
 
Secondary Antibodies 
 
Reactivity Manufacturer Catalogue number Conjugate Applications 
Goat Jackson ImmunoResearch 705-095-147 FITC
(§)
 IHC
(*)
, FC
(*)
 
Goat Jackson ImmunoResearch 705-025-147 TRITC
(§)
 IHC
(*)
 
Goat Jackson ImmunoResearch 705-175-147 Cy
(§)
5 IHC
(*)
, FC
(*)
 
Goat Jackson ImmunoResearch 705-605-147 Alexa Fluor 647 IHC
(*)
, FC
(*)
 
Goat Jackson ImmunoResearch 705-475-003 DyLight 405 IHC
(*)
 
Hamster Jackson ImmunoResearch 107-166-142 Cy
(§)
3 IHC
(*)
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Hamster Jackson ImmunoResearch 107-606-142 Cy
(§)
5 IHC
(*)
 
Hamster Jackson ImmunoResearch 107-475-142 DyLight 405 IHC
(*)
 
Rabbit  Life Technologies A21206 Alexa Fluor 488 IHC
(*)
, FC
(*)
 
Rabbit Life Technologies A10042 Alexa Fluor 568 IHC
(*)
 
Rabbit Jackson ImmunoResearch 711-605-152 Alexa Fluor 647 IHC
(*)
, FC
(*)
 
Rabbit eBioscience 12-4739-81 PE(§) FC(*) 
Rabbit Jackson ImmunoResearch 711-475-152 DyLight 405 IHC
(*)
 
Mouse  Jackson ImmunoResearch 715-025-140 TRITC
(§)
  IHC
(*)
 
Mouse  Jackson ImmunoResearch 715-605-140 Cy
(§)
5 IHC
(*)
 
Mouse Jackson ImmunoResearch 715-095-150 FITC
(§)
 IHC
(*)
 
Mouse Jackson ImmunoResearch 715-025-150 TRITC
(§)
 IHC
(*)
 
Mouse Jackson ImmunoResearch 715-175-150 Cy
(§)
5 IHC
(*)
 
Mouse Jackson ImmunoResearch 715-475-150 DyLight 405 IHC
(*)
 
Rat Jackson ImmunoResearch 712-095-150 FITC
(§)
 IHC
(*)
, FC
(*)
 
Rat Jackson ImmunoResearch 712-025-150 TRITC
(§)
 IHC
(*)
 
Rat Vector SK-4100 HRP
(§)
 IHC
(*)
 
 
(*)
 IHC= immunohistochemistry; FC= flow cytometry 
(§)
 APC=allophycocyanin; PE= phycoerythrin;
 
FITC= fluorescein isothiocyanate; TRITC= tetramethylrhodamine; 
Cy= Cyanine; HRP= Horseradish peroxidase 
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Supporting Information Figures and Figure Captions 
 
S2 Fig 1. Left ventricular coronary artery ligation.  Myocardial infarction (MI) was induced 
in female mice to reduce biological variability related to sex at 2-3 months of age as follows: 
animals were anesthetized with isoflurane 1.5% and ventilated, under sterile conditions the 
thorax was opened via the third costal space, the atrial appendage elevated, the left coronary 
artery, and a silk braided suture (6-0) was inserted and tightened around the vessel near the 
origin. Then, the chest was closed and pneumothorax reduced by negative pressure, and the 
animals were allowed to recover. Sham-operated (SHAM) mice were subjected to an identical 
surgery procedure, with the exception that the suture was not tightened around the artery. Non-
operated (NO) mice served as additional controls. 
S2 Fig 2. Experimental model and time dependent observation. At the time of sacrifice, with 
the animals (MI animals, sham and controls) under deep anesthesia, bilateral thoracotomy was 
performed, the hearts were removed and either fixed and processed for histological analysis, or 
enzymatically digested for single-cell assessment by flow-cytometry, as described in the 
materials and methods. We chose as time points: 4h and 8h, 2 days, 14 days and 30 days after MI 
in order to analyze chronic and acute processes of wound healing.  
S2 Fig 3. Flow-cytometry analysis of the podoplanin co-expression with LYVE-1 in cardiac 
cells from non-operated (NO), sham-operated (SHAM) and infarcted (MI) mice at 2 days 
after surgery. (A,B) Isolated cardiac cells were co-stained with podoplanin and the indicated 
antibodies. (A) LYVE-1. Representative scatterplots are shown. Numbers indicate proportions of 
LYVE-1-positive cells within total podoplanin-positive populations (calculated as % cells in Q2 
out of the sum of Q1 and Q2). Samples labeled with non-immune IgGs (IgGs) and podoplanin 
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only or LYVE-1 only were used to determine the gates and calculate background. (B) Frequency 
(%) of podoplanin-positive cells co-labeled with PECAM-1, CD34, Prox-1, or VEGFR-3, 
respectively, was calculated as in (A). Graphs displaying values for the individual hearts and the 
respective means for each group (red lines) are shown. PECAM-1: ns, not significant; *P = 
0.0001 by one-way ANOVA. CD34: ns, not significant for SHAM vs. MI by two-tailed t-test. 
Prox-1: *P = 0.0036 for SHAM vs. MI by two-tailed t-test. VEGFR-3: ns, not significant by 
one-way ANOVA.  
S2 Fig 4. Flow-cytometry analysis of the podoplanin co-expression with PDGFRα and 
PDGFRβ in cells from the infarcted (MI) hearts at 2 days after surgery. Representative 
scatterplots (left) and the summary graph (right) displaying individual values for each heart with 
the respective means of the frequency of podoplanin-positive cells co-labeled with PDGFRα or 
PDGFRβ are shown. Calculated as % cells in gate Q6 out of the sum of the gates Q5 and Q6. 
Samples labeled with non-immune IgGs (IgGs) and podoplanin only, or PDGFRα or PDGFRβ 
only (PDGFR only), were used to determine the gates and calculate background.  
S2 Fig 5. Low expression of myelo-monocytic markers in the podoplanin-positive 
interstitial cells. (A) Thin cardiac sections 1 month after MI were indirectly immunolabeled 
with podoplanin (red) and a combination of CD11b and Ly6C (green) antibodies. Nuclei, blue. 
Area in rectangle is shown at a higher magnification in the adjacent images for each color 
channel and merged. (B) Flow-cytometry analysis of the podoplanin co-expression with Ly6C in 
cardiac cells from the infarcted (MI) mice at 2 days after surgery. Isolated cells were co-stained 
with podoplanin and Ly6C antibodies. Representative scatterplots (left) and the graphs 
displaying individual values with the respective mean (right) are shown. Samples labeled with 
non-immune IgGs (IgGs) and podoplanin only or Ly6C only were used to determine the gates 
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and calculate the background. Data showing frequencies of double-positive cells within 
podoplanin-labeled populations in each heart (n=4) was calculated as % cells in gate 2 out of the 
sum of % cells in gate 1 and gate 2.  
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